Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111666 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101
A Phase 1 study, sponsored by Alector.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT04111666 is a Phase 1 study that has completed, run by Alector. The registered enrollment target is 88 participants.
The verdict
NCT04111666, a Phase 1 study, has completed, sponsored by Alector.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
A first in human phase 1 study in healthy volunteers to assess AL101 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics
Interventions
- OTHER Placebo
- BIOLOGICAL AL101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2019-12-14 |
| Est. Completion | 2022-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04111666
The ClinicalTrials.gov registry entry for NCT04111666 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alector, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04111666 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04111666 about?
NCT04111666 is a clinical study titled "A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101". A first in human phase 1 study in healthy volunteers to assess AL101 safety, tolerability, bioavailability, pharmacokinetics, and pharmacodynamics
What is the current status of trial NCT04111666?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2019-12-14. Estimated completion is 2022-06-09.
What interventions are being tested in trial NCT04111666?
The interventions under investigation include: Placebo (OTHER), AL101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04111666?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.